Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AK105 |
| Synonyms | |
| Therapy Description |
Penpulimab-kcqx (AK105) is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513). Penpulimab-kcqx (AK105) is FDA-approved for use as monotherapy for adult patients with metastatic non-keratinizing nasopharyngeal carcinoma (NPC) that progressed on prior therapy, and in combination with cisplatin or carboplatin and gemcitabine as first-line treatment for adult patients with recurrent or metastatic non-keratinizing NPC (FDA.gov). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AK105 | Penpulimab-kcqx | AK-105|AK 105|Penpulimab | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Penpulimab-kcqx (AK105) is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513). Penpulimab-kcqx (AK105) is FDA-approved for use as monotherapy for adult patients with metastatic non-keratinizing nasopharyngeal carcinoma (NPC) that progressed on prior therapy, and in combination with cisplatin or carboplatin and gemcitabine as first-line treatment for adult patients with recurrent or metastatic non-keratinizing NPC (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|